DIFFUSION PHARMACEUTICALS INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 26, 2021, Diffusion Pharmaceuticals Inc. (the "Company") received a written notice (the "January Notice") from the staff (the "Staff") of the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company's common stock had closed above $1.00 per share for the previous ten (10) consecutive business days.

As previously reported, on October 9, 2020, the Company received a written notice from the Staff indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company's common stock had closed below $1.00 per share for the previous 30 consecutive business days. The January Notice confirmed this matter is now closed.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses